Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Bateman Horne Center
Study ID
NCT06316843
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Valacyclovir celecoxib dose 1 — DRUG
    1500 mg valacyclovir 200 mg celecoxib taken two times a day
  • Valacyclovir celecoxib dose 2 — DRUG
    750 mg valacyclovir 200 celecoxib mg taken two times a day
  • Placebo — DRUG
    Placebo capsules colored matched to investigational product taken two times a day

Study Details

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

Key Dates

Start date
Oct 15, 2023
Status verified
Oct 2024
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024

Study Design

Enrollment
59 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1500 Valacyclovir 200 Celecoxib
    Treatment will consist of four blue 375mg valacyclovir capsules and one white 200 mg celecoxib capsule
  • Experimental: 750 Valacyclovir 200 Celecoxib
    Treatment will consist of two blue 375mg valacyclovir capsules, two blue placebo capsules, and one white 200 mg celecoxib capsule
  • Placebo Comparator: Matched Color Placebo Capsules
    Treatment will consist of four blue placebo capsules and one white placebo capsule

Primary Outcome Measure

Fatigue assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Instrument [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bateman Horne CenterSalt Lake CityUtah84102-

Find similar trials in Salt Lake City, UT

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Bateman Horne Center· Salt Lake City, UT

Related Studies